Trelstar LA Side Effects
Please note - some side effects for Trelstar LA may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
|
For the consumer For the professional
|
|
Side Effects of Trelstar LA - for the consumer
Trelstar LA
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Trelstar LA:
Seek medical attention right away if any of these SEVERE side effects occur when using Trelstar LA:Blood in the urine; bone pain; diarrhea; difficulty urinating; dizziness; headache; hot flashes; itching, pain, or swelling at the injection site; leg pain; nausea; sleeplessness; stomach discomfort; tiredness; vomiting; worsening of pain for several days.
TopSevere allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; decreased sexual ability (erectile dysfunction); severe drowsiness; severe headache; shortness of breath; swelling of the feet or legs; tingling or numbness in the hands, legs, or feet; unusual fatigue; unusual or one-sided weakness; urinary retention; urinary tract infection; vision changes.
For the professional
Trelstar LA
In the majority of patients, testosterone levels increased above baseline during the first week following the initial injection, declining thereafter to baseline levels or below by the end of the second week of treatment. The transient increase in testosterone levels may be associated with temporary worsening of disease signs and symptoms, including bone pain, hematuria, and bladder outlet obstruction. Isolated cases of spinal cord compression with weakness or paralysis of the lower extremities have occurred.
In a controlled, comparative clinical trial, the following adverse reactions were reported to have a possible or probable relationship to therapy as ascribed by the treating physician in 1% or more of the patients receiving triptorelin (Table 3). Often, causality is difficult to assess in patients with metastatic prostate cancer. Reactions considered not drug-related or unlikely to be related are excluded.
| TABLE 3. TREATMENT-RELATED ADVERSE EVENTS REPORTED BY 1% OR MORE OF PATIENTS DURING TREATMENT WITH Trelstar LA | ||
|---|---|---|
| Trelstar LA | ||
| N=174 | ||
| Adverse Event | N | % |
| *Expected pharmacologic consequences of testosterone suppression. | ||
| Application Site | ||
| Injection site pain | 7 | 4.0 |
| Body As A Whole | ||
| Hot Flushes* | 127 | 73.0 |
| Leg pain | 9 | 5.2 |
| Pain | 6 | 3.4 |
| Back pain | 5 | 2.9 |
| Fatigue | 4 | 2.3 |
| Chest pain | 3 | 1.7 |
| Asthenia | 2 | 1.1 |
| Peripheral edema | 2 | 1.1 |
| Cardiovascular | ||
| Hypertension | 7 | 4.0 |
| Dependent edema | 4 | 2.3 |
| Central and Peripheral Nervous System | ||
| Headache | 12 | 6.9 |
| Dizziness | 5 | 2.9 |
| Leg cramps | 3 | 1.7 |
| Endocrine | ||
| Breast pain | 4 | 2.3 |
| Gynecomastia | 3 | 1.7 |
| Gastrointestinal | ||
| Nausea | 5 | 2.9 |
| Constipation | 3 | 1.7 |
| Dyspepsia | 3 | 1.7 |
| Diarrhea | 2 | 1.1 |
| Abdominal pain | 2 | 1.1 |
| Liver and Biliary System | ||
| Abnormal hepatic function | 2 | 1.1 |
| Metabolic and Nutritional | ||
| Edema in legs | 11 | 6.3 |
| Increased alkaline phosphatase | 3 | 1.7 |
| Musculoskeletal System | ||
| Skeletal pain | 23 | 13.2 |
| Arthralgia | 4 | 2.3 |
| Myalgia | 2 | 1.1 |
| Psychiatric | ||
| Decreased libido* | 4 | 2.3 |
| Impotence* | 4 | 2.3 |
| Insomnia | 3 | 1.7 |
| Anorexia | 3 | 1.7 |
| Respiratory System | ||
| Coughing | 3 | 1.7 |
| Dyspnea | 2 | 1.1 |
| Pharyngitis | 2 | 1.1 |
| Skin and Appendages | ||
| Rash | 3 | 1.7 |
| Urinary System | ||
| Dysuria | 8 | 4.6 |
| Urinary retention | 2 | 1.1 |
| Vision Disorders | ||
| Eye pain | 2 | 1.1 |
| Conjunctivitis | 2 | 1.1 |
Changes in Laboratory Values During Treatment: The following abnormalities in laboratory values not present at baseline were observed in 10% or more of patients at the Day 253 visit: decreased hemoglobin and RBC count and increased glucose, BUN, SGOT, SGPT, and alkaline phosphatase. The relationship of these changes to drug treatment is difficult to assess in this population.
Pituitary apoplexy: During post-marketing surveillance, rare cases of pituitary apoplexy (a clinical syndrome secondary to infarction of the pituitary gland) have been reported after the administration of gonadotropin-releasing hormone agonists. In a majority of these cases, a pituitary adenoma was diagnosed with a majority of pituitary apoplexy cases occurring within 2 weeks of the first dose, and some within the first hour. In these cases, pituitary apoplexy has presented as sudden headache, vomiting, visual changes, ophthalmoplegia, altered mental status, and sometimes cardiovascular collapse. Immediate medical attention has been required.
TopMore resources:
Trelstar Depot - Includes detailed dosage instructions.
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
